Skaneuro AB
- Address
- Skaneuro Privatmott, Masvagen 14a, S:t Peters Kloster, 227 33 Lund, Sweden
Skaneuro AB - Specialized Migraine Research Center
Skaneuro AB is a dedicated clinical research center specializing in advanced migraine therapeutics and headache disorders. The center focuses on evaluating novel CGRP antagonist therapies and innovative treatment strategies for both acute and preventive migraine management, including studies for patients with medication overuse headache and those who have failed traditional therapies.
- Acute migraine treatment trials with CGRP antagonists (atogepant and rimegepant)
- Preventive migraine therapy for patients with inadequate response to oral preventive medications
- Chronic migraine and medication overuse headache management with eptinezumab
- Alternative treatment strategies for adults unsuitable for triptan use
The research center conducts comprehensive Phase 4 trials evaluating both efficacy and tolerability profiles of next-generation migraine medications. Skaneuro AB's studies include both double-blind, placebo-controlled designs and open-label extensions, examining treatment consistency across multiple migraine attacks and addressing the critical need for effective therapies in patients with refractory migraine and complex headache presentations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Pfizer Inc.2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 188 other sites in Sweden
Therapeutic Area Benchmark — Sweden
Select a therapeutic area to compare against other sites in Sweden.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Sweden
Market Share
Country: Sweden
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Skaneuro AB
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Evaluation of Atogepant in Acute Migraine Treatment: A Randomized, Double-Blind, Placebo-Controlled Study | AbbVie Deutschland GmbH & Co. KG | Phase III | Not Recruiting | Apr 2024 | — |
IMP list
lock Showing 1 of 3 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Rimegepant | 2 | Unknown | 2023-03-14 | 2023-03-14 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.